These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37418320)

  • 1. A Modular Chemistry Platform for the Development of a Cereblon E3 Ligase-Based Partial PROTAC Library.
    Almodóvar-Rivera CM; Zhang Z; Li J; Xie H; Zhao Y; Guo L; Mannhardt MG; Tang W
    Chembiochem; 2023 Oct; 24(20):e202300482. PubMed ID: 37418320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation.
    Xie H; Li C; Tang H; Tandon I; Liao J; Roberts BL; Zhao Y; Tang W
    J Med Chem; 2023 Feb; 66(4):2904-2917. PubMed ID: 36749666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligands for cereblon: 2017-2021 patent overview.
    Kazantsev A; Krasavin M
    Expert Opin Ther Pat; 2022 Feb; 32(2):171-190. PubMed ID: 34704527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.
    Nie X; Zhao Y; Tang H; Zhang Z; Liao J; Almodovar-Rivera CM; Sundaresan R; Xie H; Guo L; Wang B; Guan H; Xing Y; Tang W
    Chembiochem; 2024 Feb; 25(4):e202300685. PubMed ID: 38116854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
    Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
    Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
    Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
    Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
    Singh H; Agrawal DK
    Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
    Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
    Eur J Med Chem; 2021 Nov; 223():113645. PubMed ID: 34217059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
    Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
    J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
    Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
    Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
    Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
    J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. USP15 antagonizes CRL4
    Nguyen TV
    Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
    Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
    Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Buchwald-Hartwig Protocol to Enable Rapid Linker Exploration of Cereblon E3-Ligase PROTACs*.
    Hayhow TG; Borrows REA; Diène CR; Fairley G; Fallan C; Fillery SM; Scott JS; Watson DW
    Chemistry; 2020 Dec; 26(70):16818-16823. PubMed ID: 32706492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
    Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
    Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
    Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
    Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.